Stock AnalizAni Pharmaceuticals Inc. ANIP
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Ani Pharmaceuticals Inc. (ANIP) is a healthcare company listed in the US with a market value of about $1.6B. In the twelve months to September 30, 2026 it had revenue of $1.0B and net income of $117M, a net margin of 11.2%.
Its overall Stock Analiz score is 3.2 out of 5 (average). The strongest part is value (4/5); the weakest is track record (1/5).
Key numbers: a P/E of 14.3, a price to free cash flow of 7.9, 5-year revenue growth of 33% a year, a 5-year average ROIC of 1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 55% above the current price.
Score: 3.2 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
Checks not passed
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
- Liabilities below 60% of assets
- Share count down over 3 years (buybacks)
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B | $883M | $614M | $487M | $316M | $216M | $208M | $207M | $202M | $177M | $129M |
| Net income | $117M | $78M | -$19M | $19M | -$48M | -$43M | -$23M | $6M | $15M | -$1M | $4M |
| Free cash flow | $205M | $171M | $48M | $110M | -$40M | $765000 | $9M | $39M | $61M | $29M | $23M |
| EPS (diluted) | $5.01 | $3.32 | $-1.04 | $0.85 | $-3.05 | $-3.40 | $-1.88 | $0.50 | $1.30 | $-0.09 | $0.34 |
| Net margin | 11.2% | 8.9% | -3.0% | 3.9% | -15.1% | -19.7% | -10.8% | 2.9% | 7.7% | -0.6% | 3.1% |
| ROIC | — | 10.5% | 0.1% | 6.1% | -4.5% | -4.9% | -3.6% | 3.2% | 10.2% | 7.4% | 5.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 8 analysts is $103.38, 45% above the current price; targets range from $85.00 to $121.00; the consensus rating is “Buy”; expected EPS is $9.51 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Ani Pharmaceuticals’s P/E ratio?
About 14.3, based on the last twelve months of diluted earnings per share (forward P/E about 7.6).
Is Ani Pharmaceuticals stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 55% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Ani Pharmaceuticals pay a dividend?
Not currently.
Is Ani Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Ani Pharmaceuticals scores 3.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.